Tucson, AZ, September 20, 2018 – Regulonix Holding, Inc., a Tucson based biotechnology start-up company focused on developing non-opioid therapeutics to relieve chronic pain, recently formed a Scientific Advisory Board (SAB) to provide pre-clinical development guidance for the company’s internationally-patented lead compounds. The SAB consists of:
- Frank Porreca, PhD – Professor of Neuroscience, Pharmacology, Cancer Biology and Anesthesiology, University of Arizona
- Amol Patwardhan, MD, PhD – Assistant Professor, Department of Anesthesiology and Pharmacology, College of Medicine, Co-Director, Comprehensive Pain Management, University of Arizona
- Kathleen Rodgers, PhD – Associate Director, Translational Neuroscience, Professor, Pharmacology, University of Arizona
- Gerald Zamponi, PhD – Senior Associate Dean for research at the Cumming School of Medicine, University of Calgary
“These highly respected scientists will help Regulonix create more detailed roadmaps for our lead compounds,” said Rajesh Khanna, Chief Scientific Officer of Regulonix. “As demonstrated at our recently held inaugural SAB meeting, their expertise, engagement and ideas will lead to exciting future contributions for our development program.”
For more information about these pain pharmacology, therapeutics development, and voltage-gated calcium channel experts, see https://regulonix.com/leadership/.
Regulonix is an early-stage biotechnology company developing non-opioid drugs for chronic pain. Our science approaches the issue of treating pain in an entirely new way that is targeted and highly selective, resulting in non-addictive solutions. Our unique platform helps address a global pain management therapeutics market projected to reach $83B by 2024, affecting more than 100 million Americans and 1.5 billion people globally. For more information, visit www.regulonix.com